Monday 14:14
Pfizer buys Metsera to expand its portfolio in the field of obesity drugs, paying 4.9 billion dollars
Cristina Petrache
Economy
Foto DW labs Incorporated / Shutterstock.com
By acquiring Metsera, Pfizer aims to engage in the expanding market of obesity medications, paying $47.50 per share, with bonuses tied to clinical objectives. Metsera develops innovative treatments for obesity and cardiometabolic diseases, having promising candidates in its portfolio. The transaction, approved by the boards of directors, will be finalized by the end of 2025, pending necessary approvals. This will allow Pfizer to compete with current market leaders, such as Novo Nordisk and Eli Lilly.
Sources
Pfizer va cumpăra producătorul de medicamente pentru obezitate Metsera pentru 4,9 miliarde de dolari
Pfizer va cumpăra producătorul de medicamente pentru obezitate Metsera pentru 4,9 miliarde de dolari
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Pfizer își extinde portofoliul: Gigantul farmaceutic cumpără producătorul de medicamente pentru obezitate Metsera
Pfizer, aproape să finalizeze achiziţia grupului Metsera pentru 7,3 miliarde de dolari - Financial Times
ȘTIRI PE ACELEAȘI SUBIECTE
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
